[1] Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology, 2023, 77(5):1797-1835. [2] Teng ML, Ng CH, Huang DQ, et al. Global incidence and prevalence of nonalcoholic fatty liver disease. Clin Mol Hepatol, 2023, 29(Suppl):S32-S42. [3] Younossi ZM, Zelber-Sagi S, Henry L, et al. Lifestyle interventions in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol, 2023, 20(11):708-722. [4] Liu C, Liu T, Zhang Q, et al. New-onset age of nonalcoholic fatty liver disease and cancer risk. JAMA Netw Open, 2023, 6(9):e2335511. [5] Dai JJ, Zhang YF, Zhang ZH. Global trends and hotspots of treatment for nonalcoholic fatty liverdisease: A bibliometric and visualization analysis (2010-2023). World J Gastroenterol, 2023, 29(37):5339-5360. [6] 魏倩,李蕾,曾晓清,等.药物性肝损伤患者的临床特征及预后相关危险因素分析.中华肝脏病杂志,2024,32(3):214-221. [7] 中国医药生物技术协会药物性肝损伤防治技术专业委员会,中华医学会肝病学分会药物性肝病学组.中国药物性肝损伤诊治指南(2023年版).中华肝脏病杂志,2023,31(4):355-384. [8] Salolin Vargas VP, Gasbarra M, Calderon-Martinez E, et al. Non-alcoholic fatty liver disease and drug induced liver injury: A metabolic storm waiting to happen. World J Hepatol, 2025, 17(3):105255. [9] Liu YH, Guo Y, Xu H, et al. Impact of non-alcoholic simple fatty liver disease on antituberculosis drug-induced liver injury. Infect Drug Resist, 2021, 14:3667-3671. [10] Shen Y, Liu J. Influence of metabolic dysfunction-associated steatotic liver disease on antituberculosis drug-induced liver injury. Medicine (Baltimore), 2025, 104(35):e44078. [11] 中华医学会肝病学分会. 代谢相关(非酒精性)脂肪性肝病防治指南(2024年版). 中华肝脏病杂志, 2024, 32(5):418-434. [12] 中国医药生物技术协会药物性肝损伤防治技术专业委员会,中华医学会肝病学分会药物性肝病学组. 中国药物性肝损伤诊治指南(2023年版). 中华肝脏病杂志, 2023, 31(4):355-384. [13] Shen Y, Liu J. Influence of metabolic dysfunction-associated steatotic liver disease on antituberculosis drug-induced liver injury. Medicine (Baltimore), 2025, 104(35):e44078. [14] Liu S, Wang L, Zhu L, et al. Mechanism and regulation of mitophagy in liver diseases: a review. Front Cell Dev Biol, 2025, 13:1614940. [15] Devarbhavi H, Asrani SK, Arab JP, et al. Global burden of liver disease: 2023 update. J Hepatol, 2023, 79(2):516-537. [16] Di Pietro G, Chiarelli F, Mohn A. Glucagon in pediatric metabolic disorders: Pathophysiology and therapeutic perspectives. Pediatr Rep, 2025, 17(5):104. [17] Ge T, Wang Y, Han Y, et al. Exploring the updated roles of ferroptosis in liver diseases: Mechanisms, regulators, and therapeutic implications. Cell Biochem Biophys, 2025, 83(2):1445-1464. [18] Kumar A, Arora A, Choudhury A, et al. Impact of diabetes, drug-induced liver injury, and sepsis on outcomes in metabolic dysfunction associated fatty liver disease-relatedacute-on-chronic liver failure. Am J Gastroenterol, 2025, 120(4):816-826. [19] Szkultecka-Dębek M, Buła L, Skowron A, et al. Prevalence of polypharmacy among patients with chronic liver disease-A narrative literature review. J Clin Med, 2025, 14(17):6263. [20] Beridze M, Beridze D, Mkhatvari T, et al. Drug acute liver failure in children caused by anthelmintic agents (Albendazole): Treatment strategy. Exp Clin Transplant, 2024, 22(Suppl 5):83-89. |